Sol-Gel Technologies (SLGL) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
6 Jun, 2025Executive summary
First quarter 2025 revenue increased to $1.0 million from $0.5 million year-over-year.
Net loss widened to $8.8 million, or $3.2 per share, compared to $6.3 million, or $2.3 per share, in Q1 2024.
Cash, cash equivalents, and deposits totaled $16.9 million as of March 31, 2025.
Financial highlights
Research and development expenses rose to $8.8 million, up $3.5 million year-over-year, mainly due to SGT-610 manufacturing and commercialization efforts.
General and administrative expenses decreased to $1.3 million from $1.8 million, reflecting cost-saving measures.
Operating loss increased to $9.1 million from $6.7 million year-over-year.
Outlook and guidance
Cash resources are expected to fund operations into the first quarter of 2027.
Latest events from Sol-Gel Technologies
- 2025 revenue grew to $19.4M, net loss narrowed, and SGT-610 Phase 3 trial reached full enrollment.SLGL
Q4 202519 Mar 2026 - SGT-610 aims to be the first preventive therapy for Gorlin syndrome, targeting a $600M+ market.SLGL
Corporate presentation16 Mar 2026 - Dermatology innovator seeks up to $120M via shelf registration after global licensing and share split.SLGL
Registration Filing16 Dec 2025 - Q3 2025 featured higher R&D costs, expanded licensing, and a net loss amid global growth plans.SLGL
Q3 202520 Nov 2025 - Revenue surged to $11.5M in 2024 as net loss narrowed and key U.S. assets were monetized.SLGL
Q4 202410 Sep 2025 - Q2 2025 revenue jumped to $17.2M and net income hit $11.6M, with cash runway into 2027.SLGL
Q2 202519 Aug 2025 - Revenue up, net loss down, and pipeline plus licensing deals drive future growth.SLGL
Q3 202413 Jun 2025 - Q2 revenue jumped to $5.4M with net income of $2.0M, extending cash runway into 2026.SLGL
Q2 202413 Jun 2025